Curis (CRIS)
(Delayed Data from NSDQ)
$6.32 USD
+0.15 (2.43%)
Updated Jul 23, 2024 04:00 PM ET
After-Market: $6.31 -0.01 (-0.16%) 7:04 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Price, Consensus and EPS Surprise
CRIS 6.32 +0.15(2.43%)
Will CRIS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CRIS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CRIS
What Makes Curis (CRIS) a New Buy Stock
Strength Seen in Curis (CRIS): Can Its 19.5% Jump Turn into More Strength?
CRIS: What are Zacks experts saying now?
Zacks Private Portfolio Services
2seventy bio, Inc. (TSVT) Expected to Beat Earnings Estimates: Should You Buy?
Pharming Group N.V. Sponsored ADR (PHAR) Soars 14.7%: Is Further Upside Left in the Stock?
Curis (CRIS) Reports Q2 Loss, Misses Revenue Estimates
Other News for CRIS
Curis to Present at Upcoming Healthcare Conference in July
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
12 Health Care Stocks Moving In Monday's Intraday Session
Buy Rating Affirmed on Curis’s Emavusertib for Its Potential to Overcome Drug Resistance in AML and MDS
Biotech Alert: Searches spiking for these stocks today